Project Grant R41CA302074
Award Date 9/2/25
Completion Date 8/31/26
Dollars Obligated $400K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Winston-Salem, NC 27101, USA
Similar Awards
- This $375,134 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a novel approach for reducing the off-target accumulation of chemotherapeutic nanomedicines. The key objectives are to characterize an innate immune response that can be leveraged to limit nanoparticle deposition in healthy tissues, thereby enhancing delivery to tumors and improving the efficacy of chemotherapy. The 5-year project, starting on March 1, 2025,...
- This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports the development of a novel, targeted small molecule inhibitor called TRE-515 by Trethera Corp, a clinical-stage biopharmaceutical company based in California. The $1,150,000 award will fund preclinical studies to evaluate TRE-515, which targets the deoxycytidine kinase (DCK) enzyme, as a potential combination therapy to prevent the DCK-mediated resistance mechanism in...
- This National Science Foundation (NSF) SBIR Phase I Project Grant awarded to Eascra Biotech, Inc. is focused on developing and advancing regulatory pathways for space-made Janus Base Nanoparticles (JBNPs) as an innovative drug delivery system for treating solid tumors. The $274,990 award, granted on December 15, 2024, aims to demonstrate the comparability of space-manufactured JBNPs to earth-made counterparts, with the goal of revolutionizing cancer treatment by providing a versatile and more...
- The National Cancer Institute (NCI) awarded Shasqi Inc., a biotechnology company based in San Francisco, a $1,094,189 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395). The funding supports Shasqi's development of its Click Activated Protodrugs (CAPAC) platform, which aims to improve the therapeutic efficacy of cancer treatments by facilitating precise and localized activation of potent cytotoxic drugs. This approach seeks to minimize systemic toxicity and...
- The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $1,233,778 Project Grant to Matrisome Bio, Inc. to develop an extracellular matrix-targeted theranostic radiopharmaceutical for treating metastatic lung cancer. The funding will support research and development efforts to create molecularly targeted drugs using nanobodies that specifically bind to disease-associated extracellular matrix proteins in lung tumors and metastases. This novel approach aims to...
- This federal Project Grant award, funded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), provides $400,000.00 to Onconaut Therapeutics Inc. to develop novel combination therapies for the treatment of colorectal cancer. The project aims to evaluate the efficacy of combining FOLFIRI chemotherapy with CHD1L inhibitors (OTI-600 series), which have demonstrated antitumor activity as single agents and potential synergistic effects when combined with...
- This Project Grant award, valued at $305,000.00 and provided by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program, supports the development and commercialization of a novel light-activatable nanoplatform for the targeted delivery of photodynamic therapy (PDT) and chemotherapy to treat peritoneal metastasis. The nanoplatform is designed to selectively eliminate cancer cells that could not be removed by surgery, with the goal of...
- The National Cancer Institute awarded a Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395) to Georgia State University Research Foundation Inc. to develop novel covalent anti-cancer drugs using Phosphorus Fluoride Exchange (PFEX) click chemistry. The $406,258 grant, awarded on July 15, 2025, aims to synthesize PFEX warheads with tunable stability and reactivity, and evaluate their potential for expanding the scope of covalent drug targets beyond the commonly...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 in funding to Promilead, LLC to activate the TFEB protein and enhance the efficacy of immunotherapy for triple negative breast cancer (TNBC). The key objectives are to: Determine how TFEB expression and activation in TNBC cells can favorably modulate tumor-associated macrophages to suppress tumor growth. Prior research has shown that TFEB has tumor suppressive roles in breast...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $616,071 to The University of Texas Health Science Center at San Antonio (UTHSCSA) to develop novel adenosine receptor inverse agonists for the treatment of metastatic triple negative breast cancer (TNBC). The project, which runs from February 2025 to January 2030, involves a partnership between UTHSCSA and Riverwalk Therapeutics, Inc., a spin-off company incorporated by UTHSCSA....